Grigoris Gerotziafas on VTE in MM and BCMA: We Are Pleased to Announce Our New Systematic Review
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn
about a recent article he and his colleagues co-authored, adding:
”Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy: A systematic review.
We are pleased to announce our new systematic review leaded by Dr Pedro Las Casas, Associated Researcher in CaVITE Team – Thrombosis Center (G Gerotziafas), CRSA Sorbonne Univeristy:
This work was conducted by the CaVITE team (CRSA, INSERM, Sorbonne University), in collaboration with expert groups from:
- Hematology Department, University Hospital Morales Meseguer and IMIB/CIBERER, Murcia, Spain
- Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Loyola University Stritch School of Medicine, Maywood (IL), USA
- Hospital Papa Giovanni XXIII, Bergamo, Italy
- Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia
Key message: The reported incidence of venous thromboembolism (VTE) after BCMA-directed CAR T-cell therapy in multiple myeloma is low, but likely underestimated, particularly in real-world studies.
When thrombotic events are actively sought and systematically documented, VTE rates appear comparable to those expected in relapsed/refractory multiple myeloma patients receiving standard thromboprophylaxis.
These findings emphasize the need for stronger methodological rigor in assessing and reporting thrombotic complications in CAR T-cell therapy, rather than supporting definitive conclusions regarding thrombotic safety or prophylaxis adequacy.
Reference:
Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G. Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review. Br J Haematol. 2026 Feb 1. doi: 10.1111/bjh.70356. Epub ahead of print. PMID: 41622574.”
Title: Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review
Authors: Pedro Henrique Fernandes do Carmo Las Casas, Javier Marco-Ayala, Elmina-Eleftheria Lefkou, Thamiris Silva Soares, Mohammed A. Baghdadi, Prakasha Kempaiah, Jawed Fareed, Patrick Vandreden, Vania Hungria, Marina Marchetti, Anna Falanga, Laurent Garderet, Grigoris Gerotziafas
Read the Full Article on BJHaem
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?